Peptide library / Digestive & weight / PN-943
PN-943
An investigational oral peptide that stays in the gut and blocks immune cells from entering the bowel wall.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Ulcerative colitisSmall human studies
How it is thought to work
PN-943 blocks alpha-4 beta-7 integrin, the same target as the injected antibody vedolizumab, but it is taken by mouth and acts mostly in the gut.
What the evidence shows
A phase 2 trial reported higher rates of clinical remission than placebo at one dose level.
Safety and unknowns
Well tolerated in phase 2.
Regulatory status
Not approved. Development continues.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
Pramlintide
FDA-approvedA synthetic amylin analog injected at mealtimes alongside insulin.
PYY 3-36
Wellness and performanceA gut hormone released after eating that reduces hunger, studied for obesity but never approved.
Plecanatide
FDA-approvedA 16 amino acid guanylate cyclase-C agonist for constipation and irritable bowel syndrome.
General information, not medical advice. Do not buy or inject unregulated peptides.